Drug search by name

Piperacillin and Coagulation abnormalities

Result of checking the interaction of drug Piperacillin and disease Coagulation abnormalities for safety when used together.

Check result:

Piperacillin <> Coagulation abnormalities

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

The use of extended-spectrum penicillin antibiotics has rarely been associated with coagulation abnormalities manifested as prolonged prothrombin and bleeding times, abnormal platelet aggregation, purpura, and clinical bleeding. These reactions have been most severe and most frequently reported in patients with renal impairment given high dosages of the drugs for prolonged periods, although they have also occurred with usual dosages in patients with normal renal function. Therapy with extended-spectrum penicillins should be administered cautiously in patients with significantly impaired renal function, severe active bleeding, or a hemorrhagic diathesis such as hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, or thrombocytopathy. Clinical monitoring of hematopoietic and renal function is recommended during prolonged and/or high-dose therapy. Bleeding manifestations are reversible upon discontinuation of the antibiotic.

References:

"Product Information. Mezlin (mezlocillin)." Bayer, West Haven, CT.
Mehta P, Lawson D, Gross S, Graham-Pole J "Comparative effects of mezlocillin and carbenicillin on platelet function and thromboxane generation in patients with cancer." Am J Pediatr Hematol Oncol 11 (1989): 286-91
Konopka "Clinical experience with mezlocillin in Europe: an overview." J Antimicrob Chemother 9 (1982): 1-6
"Product Information. Ticar (ticarcillin)." SmithKline Beecham, Philadelphia, PA.
Lutz B, Mogabgab W, Holmes B, et al "Clinical evaluation of the therapeutic efficacy and tolerability of piperacillin." Antimicrob Agents Chemother 22 (1982): 10-4
Stuart JJ "Ticarcillin-induced hemorrhage in a patient with thrombocytosis." South Med J 73 (1980): 1084-5
Eliopoulos GM, Moellering RC "Azlocillin, mezlocillin, and piperacillin: new broad-spectrum penicillins." Ann Intern Med 97 (1982): 755-60
Russo J, Russo ME "Comparative review of two new wide-spectrum penicillins: mezlocillin and piperacillin." Clin Pharm 1 (1982): 207-16
Parry MF, Neu HC "The safety and tolerance of mezlocillin." J Antimicrob Chemother 9 (1982): 1-8
Gharpure V, Oconnell B, Schiffer CA "Mezlocillin-induced thrombocytopenia." Ann Intern Med 119 (1993): 862
Lee M, Stobnicki M, Sharifi R "Hemorrhagic complications of piperacillin therapy." J Urol 136 (1986): 454-5
Gentry LO, Jemsek JG, Natelson EA "Effects of sodium piperacillin on platelet function in normal volunteers." Antimicrob Agents Chemother 19 (1981): 532-3
Kuye O, Teal J, DeVries VG, Morrow CA, Tally FP "Safety profile of piperacillin/tazobactam in phase I and III clinical studies." J Antimicrob Chemother 31 (1993): 113-24
"Product Information. Pipracil (piperacillin)." Lederle Laboratories, Wayne, NJ.
Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ "Platelet-mediated bleeding caused by broad-spectrum penicillins." J Infect Dis 155 (1987): 1242-8
Moore M, McNamara TR, Johnson J "Elevated bleeding time and epistaxis associated with piperacillin therapy." South Med J 78 (1985): 363